Clinical Trials Browser

Phase 2 × Rectal Neoplasms × Clear all

NCT04751370 2026-03-18

Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer

Phase 2 Active not recruiting

Gastrointestinal

Rectal Neoplasms

NCT04929028 2026-03-18

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

Phase 2 Recruiting

Gastrointestinal

Anus Neoplasms, Rectal Neoplasms, HIV Infections

NCT05217446 2026-03-18

SEAMARK

Phase 2 Active not recruiting

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT05806931 2026-03-18

SCOTI

Phase 2 Recruiting

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT02437656 2026-03-16

METCAP

Phase 2 Completed

Gastrointestinal

Rectal Neoplasms

NCT06607458 2026-03-13

DEL-LIVER

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms, Colorectal Neoplasms

NCT07460596 2026-03-10

Concentrated Complex Plant Dietary Elements for Chemotherapy-Induced Diarrhea

Phase 2 Completed

Gastrointestinal

Esophageal Neoplasms, Rectal Neoplasms

NCT06647680 2026-03-06

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）

Phase 2 Recruiting

Gastrointestinal

Pathologic Complete Response, Rectal Neoplasms

NCT05731726 2026-03-05

Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT05672524 2026-03-04

A Study of Tucatinib and Trastuzumab in People With Rectal Cancer

Phase 2 Recruiting

Gastrointestinal

Adenocarcinoma, Rectal Neoplasms

NCT07176182 2026-02-27

Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression

Phase 2 Not yet recruiting

Gastrointestinal

Rectal Neoplasms

NCT07433673 2026-02-25

GAP Cemi

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT07292298 2026-02-19

Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT07337876 2026-02-17

MARS

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT05673772 2026-02-12

SOLAR

Phase 2 Active not recruiting

Gastrointestinal

Rectal Neoplasms

NCT07407647 2026-02-12

Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer

Phase 2 Recruiting

GastrointestinalGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Rectal Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

NCT07397442 2026-02-11

Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Pathologic Complete Response, Rectal Neoplasms

NCT07402486 2026-02-11

A Phase II Prospective Study of Maastro Applicator Brachytherapy for Rectal Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Rectal Neoplasms

NCT03365882 2026-02-10

S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

Phase 2 Completed

240 enrolled 14 charts

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT04963283 2026-02-10

Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer

Phase 2 Active not recruiting

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT07394192 2026-02-06

PKUCH- R11

Phase 2 Not yet recruiting

Gastrointestinal

Rectal Neoplasms

NCT00556413 2026-02-05

Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer

Phase 2 Completed

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT07381400 2026-02-03

Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Cancer (FIRM02 Study)

Phase 2 Not yet recruiting

Gastrointestinal

Rectal Neoplasms

NCT04643366 2026-01-27

Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT05009069 2026-01-22

A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer

Phase 2 Active not recruiting

Gastrointestinal

Rectal Neoplasms

NCT04505553 2026-01-21

Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer

Phase 2 Completed

78 enrolled 14 charts

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Anus Neoplasms, Appendiceal Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Carcinoma, Hepatocellular, Adenoma, Islet Cell, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms

NCT07209215 2026-01-20

ULTIMATE

Phase 2 Not yet recruiting

Gastrointestinal

Rectal Neoplasms

NCT07347951 2026-01-16

A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT00335816 2026-01-14

Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer

Phase 2 Active not recruiting

Gastrointestinal

Rectal Neoplasms, Colorectal Neoplasms

NCT05723562 2026-01-08

AZUR-1

Phase 2 Active not recruiting

Gastrointestinal

Rectal Neoplasms

NCT07068763 2026-01-06

mRCAT-E

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT03921684 2026-01-05

Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients

Phase 2 Active not recruiting

Gastrointestinal

Rectal Neoplasms

NCT07302126 2025-12-24

Preventive Efficacy of Bergmann Enema for Acute Radiation-induced Rectal Injury in Rectal Cancer Patients Undergoing Short-course Radiotherapy

Phase 2 Not yet recruiting

Gastrointestinal

Rectal Neoplasms

NCT07297030 2025-12-22

SIB-RT Combined With CAPOX and PD-1 for High-Risk Rectal Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Rectal Neoplasms

NCT07284992 2025-12-16

SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT07281768 2025-12-15

Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Adenocarcinoma, Carcinoma, Rectal Neoplasms, Colorectal Neoplasms

NCT04417699 2025-12-10

SHORT

Phase 2 Completed

13 enrolled 12 charts

Gastrointestinal

Rectal Neoplasms

NCT02921256 2025-12-04

Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer

Phase 2 Completed

363 enrolled 16 charts

Gastrointestinal

Rectal Neoplasms

NCT05358704 2025-12-04

Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer

Phase 2 Suspended

Gastrointestinal

Rectal Neoplasms

NCT07160647 2025-12-02

Neo-IT

Phase 2 Active not recruiting

Gastrointestinal

Rectal Neoplasms

NCT07248020 2025-11-25

BCMRECRAD

Phase 2 Not yet recruiting

Gastrointestinal

Rectal Neoplasms

NCT07127497 2025-11-21

Clinical Study on the Safety and Relationship of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma

Phase 2 Active not recruiting

Gastrointestinal

Rectal Neoplasms

NCT07239466 2025-11-20

A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Rectal Neoplasms

NCT01941641 2025-11-17

Colon Neoadjuvant FOLFOXIRI Study

Phase 2 Active not recruiting

Gastrointestinal

Rectal Neoplasms

NCT03997435 2025-11-17

FOLFOXIRI With or Without Intensification for Rectal Cancer

Phase 2 Active not recruiting

Gastrointestinal

Rectal Neoplasms

NCT06640049 2025-11-17

China AZUR-1

Phase 2 Active not recruiting

Gastrointestinal

Rectal Neoplasms

NCT06569368 2025-10-06

Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT07198165 2025-09-30

SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT05856305 2025-09-26

SCOTCH

Phase 2 Active not recruiting

Gastrointestinal

Rectal Neoplasms

NCT06577194 2025-09-19

A Single-Center, Single-Arm Study of Neoadjuvant Short-Course Radiotherapy With IL-2 Followed by Sequential Immunotherapy With CAPOX Combined With PD-1 Antibody and IL-2 for Locally Advanced Rectal Cancer

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms